Medical devices, healthcare technology and the business of care
PMA approval · P200010

Guardant360 CDx

Guardant Health, Inc. · Decision date Aug 7, 2020

FDA DECISIONP200010

What did the FDA approve?

FDA records P200010 as an original PMA application. The recorded decision is approval, dated Aug 7, 2020.

FDA approval order statement

Approval order for Guardant360 CDx. Guardant360 CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs), insertions and deletions (indels) in 55 genes, copy number amplifications (CNAs) in two (2) genes, and fusions in four (4) genes. Guardant360 CDx utilizes circulating cell-free DNA (cfDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). The test is intended to be used as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients who may benefit from treatment with the targeted therapy listed in Table 1 in accordance with the approved therapeutic product labeling. Table 1. Companion Diagnostic IndicationsIndication: Non-small cell lung cancer (NSCLC); Biomarker: EGFR exon 19 deletions, L858R, and T790M*; Therapy: TAGRISSO (osimertinib)A negative result from a plasma specimen does not assure that the patients tumor is negative for genomic findings. NSCLC patients who are negative for the biomarkers listed in Table 1 should be reflexed to tissue biopsy testing for Table 1 biomarkers using an FDA-approved tumor tissue test, if feasible.*The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore, testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Additionally, the test is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with solid malignant neoplasms. The test is for use with patients previously diagnosed with cancer and in conjunction with other laboratory and clinical findings. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. Guardant360 CDx is a single-site assay performed at Guardant Health, Inc.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Aug 7, 2020

FDA source record

Regulatory record facts

Identifier
P200010
Regulatory pathway
Premarket approval application
Product code
PQP
Decision code
APPR
Decision date
Aug 7, 2020
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P200010 received

    Application receipt date recorded by FDA.

  2. P200010 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P200010. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200010

Product / regulatory recordCompanyPathwayDecision dateSource
Guardant360 CDxP200010/S024
Guardant Health, Inc.PMA supplementSep 4, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Guardant Health, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
505 Penobscot Dr., Redwood City, CA, 94063

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records